Table I.
Clinical and tumor characteristics of the 112 patients included in the study.
| Parameters | Values |
|---|---|
| Age, years, mean ± SD | 60.2±10.7 |
| Sex, male (%) | 62 (55.4) |
| HBsAg, positive (%) | 26 (23.2) |
| Anti-HCV, positive (%) | 15 (13.4) |
| Cirrhosis, positive (%) | 19 (17.0) |
| ECOG stage | |
| 0 | 68 (60.7) |
| 1 | 44 (39.3) |
| Biliary tree stones, yes (%) | 24 (21.4) |
| Stone-unrelated cholangitis, yes (%) | 46 (41.0) |
| Tumor characteristics | |
| Perihilar, yes (%) | 25 (22.3) |
| Invasion to vessel, yes (%) | 30 (26.8) |
| Perineural invasion, yes (%) | 48 (42.9) |
| Periductal invasion, yes (%) | 45 (40.2) |
| Lymph node involvement, yes (%) | 33 (29.5) |
| Tumor number | |
| 1 | 101 (90.2) |
| 2 | 6 |
| 3 | 1 |
| >3 | 4 |
| Tumor size, cm, mean ± SD | 6.0±3.2 |
| Histology | |
| Well differentiated, yes (%) | 25 (22.3) |
| Mixed hepatocellular carcinoma, yes (%) | 14 (12.5) |
| Extrahepatobiliary invasion, yes (%) | 46 (41.1) |
| Resection margin involvement, yes (%) | 44 (39.3) |
| More than one segment of resection, | 98 (87.5) |
| yes (%) | |
| Biochemistry | |
| CEA, ng/ml, mean ± SD | 41.0±104.4 |
| CA-19-9, U/ml, mean ± SD | 8,648.5±26,889.6 |
| Bilirubin, mg/dl, mean ± SD | 1.8±3.1 |
| AST, U/l, mean ± SD | 56.3±69.5 |
| ALT, U/l, mean ± SD | 62.9±83.4 |
| GALNT14 genotype | |
| TT (%) | 35 (31.3) |
| TG (%) | 55 (49.1) |
| GG (%) | 22 (19.6) |
HBsAg, hepatitis B virus surface antigen; HCV, hepatitis C virus; ECOG, Eastern Co-operative Oncology Group; CEA, carcinoembryonic antigen; CA-19-9, carbohydrate antigen 19-9; AST, aspartate aminotransferase; ALT, alanine aminotransferase; SD, standard deviation.